Healthy Living BEYOND Weight: a cohort for people living with overweight or obesity.
Official title: Healthy Living BEYOND Weight Study
Run by American Heart Association · NCT07075341 · Data updated 2026-11-12
This project will follow adults with overweight or obesity to see if different real-world weight management approaches and treatments work and how they affect health over time.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 1000000 (estimated) |
| Sponsor | American Heart Association Academic / other |
| Locations | 1 site (Dallas, Texas) |
| Status | Recruiting |
| Started | June 30, 2025 |
| Main results expected | December 2060 |
| Study ends | December 2060 |
| Registry record updated | October 28, 2026 |
| Trial ID | NCT07075341 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults with a BMI of 25 kg/m2 or greater (or elevated waist circumference) or adults with BMI under 25 due to prior or current weight-management treatment who can complete surveys and allow EHR linkage are ideal candidates.
✕Probably not a fit
People who are incarcerated at enrollment, currently self-report pregnant at enrollment, have a terminal illness with life expectancy under six months, or are employed by the American Heart Association are unlikely to benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The Healthy Living BEYOND Weight project will build an inclusive cohort of people living with overweight or obesity by combining regular patient-reported surveys with linked electronic health record (EHR) data. Participants will report experiences, treatments, and outcomes through surveys while clinical encounters and measurements are captured from EHRs to document real-world care and events. The study team includes experts in obesity science, cardiometabolic health, epidemiology, implementation science, and disparities research, and will focus on contemporary, diverse populations. The observational design will allow comparison of different lifestyle, pharmacologic, and surgical management strategies and examination of long-term outcomes and patient experience.
Why it matters
Potential benefit: If successful, the findings could help patients and clinicians choose weight management approaches that work best for different people and improve prevention of cardiovascular and metabolic complications.
How similar studies have gone: Randomized trials and some observational cohorts have demonstrated efficacy of obesity therapies for weight loss and cardiometabolic risk reduction, but large linked cohorts combining patient-reported outcomes and EHR data to capture real-world, long-term impact are less common.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * BMI at the time of enrollment of 25 kg/m2 or greater or other elevated adiposity measures (e.g., waist circumference of greater than 102cm (40 in) in men or 88cm (35 in) in women) OR adults with a BMI less than 25 due to previous or current weight management treatment (lifestyle, pharmacological or surgical). Exclusion Criteria: * Incarcerated at the time of enrollment * Self-reported pregnancy at the time of enrollment. However, individuals who become pregnant after enrollment will be welcomed to continue to participate, given that the critical life period of pregnancy often has a significant impact on subsequent weight trajectories. * Terminal illness or end-stage disease with a life expectancy of less than 6-months * Employed by the American Heart Association or working on the Healthy Living BEYOND Weight Study
Where it's running
-
American Heart Association
Dallas, Texas, United States Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
GZC8072 tablets: safety and how the body handles it after a single dose in healthy people and after multiple doses in people who are overweight or obese
This study tests GZC8072 tablets to see if they are safe and how they behave in the body after a single dose in healthy adults and after repeated doses in adults who are overweight or obese.
-
Just-in-Time Practices to Prevent Weight Regain from Stopping Your Progress
This trial tests whether sending brief mindfulness and self-compassion exercises right after weight regain or a missed weigh-in helps people stick with their long-term weight goals.
-
Olatorepatide in adults who are overweight or have obesity (without diabetes) test of safety and dosing
This study tests olatorepatide versus placebo to see if it can safely help adults who are overweight or obese lose weight at different doses.
-
Metformin added to antidepressants for depression with obesity in Pakistani adults
This study tests whether adding metformin to antidepressant therapy helps reduce depressive symptoms and BMI in adults with depression and overweight/obesity in Pakistan.
-
Safety and drug levels of REGN20934 in adults with overweight or obesity
This study tests REGN20934 to see if it is safe and how it behaves in the body in adults who are overweight or have obesity.
-
SYH2082 Injection: early-dose safety in adults with overweight or obesity
This early-phase study tests whether a single dose and multiple doses of SYH2082 are safe and well tolerated in healthy adults who are overweight or have obesity.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.